School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.
Department of Hospital Office, Weifang People's Hospital, Weifang, China.
World J Microbiol Biotechnol. 2023 Sep 1;39(11):291. doi: 10.1007/s11274-023-03742-w.
Colorectal cancer (CRC) is a highly prevalent gastrointestinal cancer worldwide. Recent research has shown that the gut microbiota plays a significant role in the development of CRC. There is mounting evidence supporting the crucial contributions of bacteria-derived toxins and metabolites to cancer-related inflammation, immune imbalances, and the response to therapy. Besides, some gut microbiota and microbiota-derived metabolites have protective effects against CRC. This review aims to summarize the current studies on the effects and mechanisms of gut microbiota and microbiota-produced metabolites in the initiation, progression, and drug sensitivity/resistance of CRC. Additionally, we explore the clinical implications and future prospects of utilizing gut microbiota as innovative approaches for preventing and treating CRC.
结直肠癌（CRC）是一种在全球范围内普遍存在的胃肠道癌症。最近的研究表明，肠道微生物群在 CRC 的发展中起着重要作用。越来越多的证据支持细菌衍生的毒素和代谢物对与癌症相关的炎症、免疫失衡和对治疗的反应的关键贡献。此外，一些肠道微生物群和微生物群衍生的代谢物对 CRC 具有保护作用。本综述旨在总结目前关于肠道微生物群和微生物群产生的代谢物在 CRC 的发生、发展和药物敏感性/耐药性中的作用和机制的研究。此外，我们还探讨了利用肠道微生物群作为预防和治疗 CRC 的创新方法的临床意义和未来前景。
